565 related articles for article (PubMed ID: 24503784)
1. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Read PA; Khan FZ; Heck PM; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2010 Mar; 3(2):195-201. PubMed ID: 20075143
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.
Read PA; Khan FZ; Dutka DP
Heart; 2012 Mar; 98(5):408-13. PubMed ID: 21561896
[TBL] [Abstract][Full Text] [Related]
5. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Ishikawa S; Shimano M; Watarai M; Koyasu M; Uchikawa T; Ishii H; Inden Y; Takemoto K; Murohara T
Am J Cardiol; 2014 Aug; 114(3):384-8. PubMed ID: 24929624
[TBL] [Abstract][Full Text] [Related]
6. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
8. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
[TBL] [Abstract][Full Text] [Related]
9. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
Leung M; Leung DY; Wong VW
Diab Vasc Dis Res; 2016 May; 13(3):236-43. PubMed ID: 26993495
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
11. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Fadini GP; Boscaro E; Albiero M; Menegazzo L; Frison V; de Kreutzenberg S; Agostini C; Tiengo A; Avogaro A
Diabetes Care; 2010 Jul; 33(7):1607-9. PubMed ID: 20357375
[TBL] [Abstract][Full Text] [Related]
12. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
13. Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
Andersen ES; Lund A; Bagger JI; Andreasen C; Grøndahl MF; Deacon CF; Hartmann B; Holst JJ; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2018 Aug; 20(8):1937-1943. PubMed ID: 29654643
[TBL] [Abstract][Full Text] [Related]
14. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
15. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?
Schinkel AF; Poldermans D; Rizzello V; Vanoverschelde JL; Elhendy A; Boersma E; Roelandt JR; Bax JJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):385-90. PubMed ID: 14762345
[TBL] [Abstract][Full Text] [Related]
16. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
Read PA; Hoole SP; White PA; Khan FZ; O'Sullivan M; West NE; Dutka DP
Circ Cardiovasc Interv; 2011 Jun; 4(3):266-72. PubMed ID: 21586690
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.
Wilson JR; Brown NJ; Nian H; Yu C; Bidlingmaier M; Devin JK
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478970
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
